Real-world data confirmed the efficacy and safety profiles of tisagenlecleucel in patients with relapsed/refractory ALL younger than 3 years old.
Researchers found a significant increase in the risk of breast cancer among men who had not fathered any children.
The findings contradict results from the phase 3 BEACON study.
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
Steroid-refractory acute GVHD is associated with high mortality rates in pediatric patients, despite second-line treatment.
Overall survival was longer with ablative radiotherapy than with conventional radiotherapy.
Fasting insulin, bioavailable testosterone, and sex hormone binding globulin were found to play a role in the relationship between BMI and endometrial cancer risk.
